Abstract: Subject matter of the present invention is a combination medication for use in the treatment of a patient having acute and/or persistent dyspnea comprising at least two of the following components: a beta blocker, and one agent of the group consisting of an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II inhibitor and a combination of angiotensin II inhibitor or an angiotensin receptor-neprilysin inhibitor (ARNi), and mineralo receptor antagonist (MRA), gliflozine, a loop-acting diuretic, wherein a sample of bodily fluid of said patient has a level of BNP>200 pg/mL and/or has a level NT-proBNP>600 pg/mL, and wherein said sample of bodily fluid is selected from the group comprising blood, plasma and serum, and wherein said patient is either a patient with heart failure with left ventricular ejection fraction (LVEF) greater and equal to 40%, preferably 50%, or a patient with no heart failure.

Abstract: The present disclosure relates to safe and effective subcutaneously administered treatments for advanced Parkinson's disease.

Abstract: The invention features methods of preventing and/or treating neuropathic pain associated with diabetic peripheral neuropathy (DPN).

Abstract: The invention relates to a dosing schedule for an inositol polyphosphate oligo(ethylene glycol) compound, or its pharmaceutically acceptable salt used in the treatment or prevention of a disease associated with formation of, and/or tissue exposure to, calcium salt crystals. The drug compound is administered at an interval of one week.

Abstract: A synthetic composition comprising a carbohydrate component, a fat component and a protein component, wherein the carbohydrate component comprises lacto-N-fucopentaose III (LNFP III) and sialyllacto-N-tetraose a (LSTa), preferably wherein the weight ratio between LNFP III and LSTa is between 1:100 and 100:1.

Abstract: Methods and compositions for treating neurodegenerative diseases are provided. In one embodiment, the method includes administering gangliosides into the brain of a mammal in need of such treatment. The gangliosiges are preferably GM1 and GD3 gangliosides. The gangliosides are intranasally administered in an amount effective to delay and/or prevent disease progression, and to increase the resilience of brains by promoting adult neurogenesis by gangliosides.

Abstract: The invention disclosed herein relates to synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases. Particularly, the invention relates to synergistic nutritional compositions comprising an exogenous blend of N-acetyl-DL-leucine (NADLL) enantiomerically enriched with L-leucine and uridine monophosphate (UMP) which are present in a weight ratio of 1:0.002 to 1:0.8 along with pharmaceutically acceptable excipients. The composition of the present invention is useful for treating dizziness, imbalance, vertigo, tinnitus, hearing loss, brain fog, vision impairment, cognitive changes, Alzheimer's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), motor neurone disease (MND), multiple system atrophy (MSA), and Parkinson's disease (PD).

Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.

Abstract: Provided herein are methods for regenerating hair cells in an adult mammalian inner ear using novel combinations of agents selected from the group consisting of a histone deacetylase (HDAC) inhibitor, one or more inhibitory nucleic acids targeting Fir, Mxi1, Fbxw7, or a combination thereof, a Wnt pathway activator, and a cAMP activator. The methods and compositions can be used to treat a subject with hearing loss or vestibular dysfunction.

Abstract: The present invention provides methods for treating or preventing TTR-associated diseases using RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene.

Abstract: It is disclosed herein that RPE degeneration in human cell culture and in mouse models is driven by a non-canonical inflammasome pathway that results in activation of caspase-4 (also known as caspase-11 in mouse) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-? (IFN-?) production and gasdermin D-dependent interleukin-18 (IL-18) secretion. Reduction of DICER1 or accumulation of Alu RNA triggers cytosolic escape of mitochondrial DNA, which engages cGAS. Collectively, these data highlight an unexpected role for cGAS in responding to mobile element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial damage-induced NLRP3 activation, and expand the immune sensing repertoire of cGAS and caspase-4 to non-infectious human disease. Coupled with the unexpected result that caspase-4, gasdermin D, IFN-?, and cGAS are elevated in the RPE of human eyes with geographic atrophy, these findings also identify new targets for a major cause of blindness.

Abstract: The present disclosure provides methods and compositions that promote gut health. In some cases, the compositions comprise dietary fibers.

Abstract: The invention relates to a method of immunotherapy for prevention or treatment of cancer in a subject, the method comprising the administration of an adjuvant, or administration of an adjuvant in combination with a tumour antigen, to the subject, wherein the adjuvant comprises polyglucosamine or acetylated polyglucosamine that comprises no more than 10% N-acetyl-D-glucosamine groups, and wherein the N-acetyl-D-glucosamine groups are distributed in the acetylated polyglucosamine in blocks of two or more. The invention relates to a method of immunotherapy for solid-tumour cancer in a subject, the method comprising the administration of polyglucosamine or chitosan into the subject, wherein the administration is intratumoral and/or peritumoral.

Abstract: The invention discloses a functionalised chitosan, or a salt thereof, used in the treatment of pathologies of the respiratory tract or hepatic pathologies, preferably caused by viral infections. It was indeed observed that said functionalised chitosan or salt thereof was able to act as galectin-modulator, modulating in particular galectin-3, and therefore determining a marked reduction in the inflammatory and fibrotic cascade generated by these viral infections. The invention moreover discloses a pharmaceutical composition, as well as a biomaterial, comprising this functionalised chitosan, or a salt thereof.

Abstract: Disclosed in certain embodiments are skincare formulations and treatment methods having hyaluronic acid, or its associated salts, and one or more of ascorbic acid, glycolic acid or lactic acid. In certain embodiments, the formulations and treatments are applied to the skin during and/or before and/or after dermatological procedures that affect the skin's barrier for alleviating patient discomfort and enabling rapid healing of irritated and damaged skin.

Abstract: Provided herein are methods for maintaining physiological levels of thiosulfate in a subject undergoing hemodialysis. Also provided herein are methods of administering pharmaceutically acceptable sodium thiosulfate to a subject undergoing hemodialysis.

Abstract: One aspect provides a pharmaceutical composition and a pharmaceutical combination formulation contains the same, the pharmaceutical composition containing as active ingredients: a proton pump inhibitor or a pharmaceutically acceptable salt thereof; and an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: This disclosure relates to novel formulations of bis-choline tetrathiomolybdate useful for treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD). For example, this disclosure relates to low dose formulations of bis-choline tetrathiomolybdate.

Abstract: In one aspect, compositions and therapeutic use thereof are provided that can inhibit ?-synuclein cell-to-cell transmission. In embodiment, methods are provided to treat a mammal such as a human that is suffering from or susceptible to an ?-synucleinopathy that include administering to the mammal an effective amount of one or more metal nanozymes.

Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.

Abstract: The present disclosure provides a method and a kit for treating an abnormal hollowed space of a subject, such as a fistula, e.g. an anal fistula or a stoma space. For example, the abnormal hollowed space can be an anal fistula, a stoma opening, or a pilonidal sinus. The method utilizes autologous blood, which is derived from the subject, by introducing it into the abnormal hollowed space and let it clot within the abnormal hollowed space thereby forming a coagulated blood mass therein, namely a blood clot, that enhances the healing process of the abnormal hollowed space. The healing may be a complete or partial closure or reduction in the size or volume of said space; or the formation of healthy tissue within the former abnormal hollowed space.

Abstract: Provided are methods and compositions for use in cancer immunotherapies. In various embodiments, the compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

Abstract: Provided is a ??T cell for securing the purity and number of cells sufficient for treatment. Also provided is a method of generating the ??T cell. More specifically, provided are homogeneous ??T cells excellent in that the ??T cells are not affected by exhaustion of the cells. The foregoing is achieved by ??T cells obtained by subjecting induced pluripotent stem cells (iPS cells) to differentiation induction treatment. Specifically, the foregoing is achieved by ??T cells generated by subjecting iPS cells having a rearranged ??TCR gene (??TCR-type iPS cells) to differentiation induction treatment. According to the method of generating the ??T cell of the present invention, there can be provided ??T cells and a cell population of ??T cells that have an excellent function of having antigen-specific cytotoxic activity in a MHC-unrestricted manner, and that are more homogeneous and have a higher effect than ??T cells separated from peripheral blood.

Abstract: Described herein are immunoresponsive cells which are useful for their preventive and therapeutic potential against autoimmune diseases and rejections of solid organ transplants.

Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR ? and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).

Abstract: The present disclosure provides novel artificial antigen presenting cells (aAPCs). The aAPCs disclosed herein comprise a liposome comprising a phospholipid and a stimulatory ligand displayed on the outer surface of the liposome. The aAPCs of the present disclosure can be used as an “off the shelf” tool to activate and expand a T cell of interest. Also, the present disclosure provides methods of activating a T cell and manufacturing a T cell therapy product using the aAPCs disclosed herein.

Abstract: This document provides methods and materials for treating multiple system atrophy. For example, methods and materials for using autologous mesenchymal stem cells (e.g., adipose derived mesenchymal stem cells) to treat multiple system atrophy are provided.

Abstract: A non-human animal or a part of the same in which the function of Mipep gene is totally or partially lost in adipose tissues or the expression level of Mipep gene in adipose tissues is lowered compared to a wild type; and mesenchymal stem cells or adipocytes in which the function of Mipep gene is totally or partially lost or the expression level of Mipep gene is lowered compared to a wild type. A therapeutic or prophylactic drug that includes the mesenchymal stem cells or adipocytes or a culture supernatant thereof; and a method for preparing a mitokine mixture using the non-human cells, mesenchymal stem cells or adipocytes.

Abstract: Provided is a composition for promotion of the regeneration of the nucleus pulposus of an intervertebral disc, said composition comprising a low endotoxin monovalent metal salt of alginic acid and mesenchymal stem cells. In particular, the composition of the present invention promotes the regeneration of the nucleus pulposus of an intervertebral disc via activation of nucleus pulposus cells by human bone marrow-derived high-purity mesenchymal stem cells and/or differentiation of human bone marrow-derived high-purity mesenchymal stem cells into nucleus pulposus cells.

Abstract: Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof. Also provided is the use of the modified mesenchymal stem cell and culture supernatant thereof, and the pharmaceutical composition comprising said cell or culture supernatant thereof in the treatment of metabolic diseases and in the preparation of a medicament for treating metabolic diseases.

Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C.

Abstract: Probiotic compositions, particularly oral compositions, comprising one or more bacteria that are capable of producing nitrite and/or nitric oxide in a subject are provided. Some compositions further comprise nitrate/nitrate, such as a botanical source of nitrate. Some compositions further comprise botanical sources of nitrate reductase. Also, provided are methods of improving the oral and/or vascular health of a subject by orally administering a composition comprising one or more bacteria capable of producing nitric oxide. Methods of repopulating the nitric oxide producing microflora and bacterial environment in the oral cavity of a subject are also provided.

Abstract: Provided herein are methods and compositions for treating and/or preventing hepatic encephalopathy involving administering to a subject a pharmaceutical composition comprising a purified bacterial mixture.

Abstract: Disclosed herein are methods and compositions useful for the treatment of Autism Spectrum Disorder (ASD). The methods and compositions include combination therapy with probiotics and oxytocin (OXT), resulting in a therapeutic synergy that exerts beneficial effects on ASD symptoms. The methods and compositions provide improvements in several measurable parameters including but not limited to: measured clinical index for ASD core symptoms, gut microbiome profile, and levels of OXT and inflammatory markers in the blood.

Abstract: Bacteriophage compositions and therapeutic uses thereof. In particular, compositions of lytic bacteriophages that are capable of lysing Propionibacterium acnes (P. acnes) bacterial strains associated with acne and biofilms, thereby treating or preventing acne and biofilms.

Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.

Abstract: Provided herein are compositions and methods of using Seneca Valley Vims (SVV) or SVV derivative in combination with a checkpoint inhibitor for treating a cancer that is refractive to treatment by the checkpoint inhibitor. Also provided herein are kits containing a Seneca Valley Vims (SVV) or SVV derivative and a checkpoint inhibitor for treating a cancer that is refractive to treatment by the checkpoint inhibitor.

Abstract: A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.

Abstract: Botanical extracts are provided, which comprise ethanol extracts of Nannochloropsis algae having between 10 wt % and 50 wt % polar lipids and between 45 wt % and 60 wt % fatty acids, wherein the fatty acids comprise more than 10 wt % of eicosapentaenoic acid (EPA) as triglyceride conjugates and/or diglyceride conjugates, and less than 15 wt % EPA as free fatty acids. EPA level may reach up to 90 wt %, and the botanical extract may be fluid at room temperature. Growth conditions are configured, adjusted and monitored to promote EPA formation in the cell vacuoles, resulting in a high proportion of EPA as tri/di-glyceride conjugates, as well as in a high concentration of ?-3 fatty acids, which merely requires gentle extraction procedures to reach the final products, thereby maintaining the biochemical of the compounds without excessive modifications.

Abstract: A method for producing composition for a pain-relieving salve by producing a decarbonated cannabinoid and placing the decarbonated cannabinoid and a predetermined amount of oil into a sealed container, placing the sealed container in a pressure cooker with a predetermined volume of liquid, pressure cooking the sealed container at a predetermined temperature for a predetermined time, cooling the sealed container to room temperature, and separating an infused oil of the sealed container by straining contents of the sealed container.

Abstract: The invention relates to a method for isolating biologically active substances from raw plant matter, and more particularly to methods for obtaining microvesicules (with a diameter of 50-1200 nm) from plants of the Amaranthaceae family. The claimed method can be used in the medical, cosmetic and food industries. The technical result of the proposed method for isolating microvesicules is the possibility of isolating microvesicules from plants of the Amaranthaceae family.

Abstract: Provided are a traditional Chinese medicine ointment for preventing and treating mastitis in dairy cows and a preparation method thereof, belonging to the technical field of veterinary traditional Chinese medicines. The traditional Chinese medicine ointment includes raw materials in parts by mass: 20-30 parts of dandelion, 20-30 parts of herba patriniae, 10-16 parts of Caulis Lonicerae Japonicae, 0.5-1 part of borneol, 0.03-0.05 part of polypeptide, 40-50 parts of auxiliary emulsifier, 40-50 parts of liquid paraffin and 100-130 parts of white vaseline. An amino acid sequence of the polypeptide is: Phe Phe Arg Lys Val Leu Lys Leu Ile Arg Lys Ile Trp Arg (SEQ ID NO. 1). In the application, dandelion, herba patriniae, Caulis Lonicerae Japonicae and borneol 1 are mixed, and polypeptide is added at the same time to prepare ointment.

Abstract: A composition for oral mucosal delivery can include at least two terpenes having anti-inflammatory properties, the at least two terpenes comprising at least one of terpinolene, beta caryophyllene, alpha pinene, linalool, alpha-terpineol, limonene; and at least two supplements having anti-inflammatory properties, the supplements comprising at least one of cat's claw root extract and boswellia root extract. In other embodiments, the composition can contain other terpenes and active compositions/supplements that have complementary effects.

Abstract: A composition to provide increased hydration and to counteract the effects of alcohol. The composition includes about 10% by weight of sunflower lecithin powder; about 2.5% by weight N-acetyl cysteine; about 1.9% by weight prickly pear cactus; and about 2.5% by weight dihydromyricetin in combination with electrolytes, sugar, and water.

Abstract: Compositions and methods from providing a digestive health benefit to a feline include the use of a prebiotic fiber blend comprising pumpkin, inulin, and, optionally, wheat bran aleurone.

Abstract: The present invention belongs to the field of drug preparation and detection, and particularly discloses a preparation method for a Eucommia ulmoides Oliv. leaf extract. The extract is obtained from Eucommia ulmoides Oliv. leaves (the mixture of the Eucommia ulmoides Oliv. leaves and Eucommia ulmoides Oliv. male flower) by enzymolysis and extraction of ethanol and water, and can effectively solve the problem that the extract is not easy to spray dry (the Eucommia ulmoides Oliv. leaves contain colloidal substances). The pharmacodynamic experiment proves that the Eucommia ulmoides Oliv. leaf extract has good effect of protecting the health of the renal function. The present invention also develops a detection method for the extract, which not only realizes the quality control of the extract, but also has the advantages of good repeatability and stability.

Abstract: A nutrition-based method for managing the behavior of a large, domesticated animal, comprising administering a nutritional formulation to a large, domesticated animal, wherein the nutritional formulation includes an effective amount of at least one suppressive neurotransmitter and an effective amount of at least one herbal estrous cycle effect moderator, and wherein the nutritional formulation moderates anxiety, reduces stress, and reduces erratic behavior in the large, domesticated animal based at least in part on the activity of the at least one suppressive neurotransmitter and the at least one herbal estrous cycle effect moderator.

Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention.

Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.

Abstract: The disclosure relates to compositions and methods of preventing, reducing, reversing or treating a subject suffering from opioid toxicity, overdose or opioid-induced respiratory depression or a subject at risk for developing opioid-induced respiratory depression. The method comprises administering to a patient in need of treatment an effective amount of oxytocin or an analog thereof.